Patents by Inventor Renee MOORE

Renee MOORE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES
    Publication number: 20240043491
    Abstract: Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 8, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Stephen E. ALVES, Glareh AZADI, Maribel BEAUMONT, Lia BENSO, Alan C. CHENG, Peter GEORGIEV, Brian E. HALL, Veronica M. JUAN, Renee MOORE, Venkataraman SRIRAMAN, Jie ZHANG-HOOVER
  • ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20220017612
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Application
    Filed: September 2, 2021
    Publication date: January 20, 2022
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Yacob Gomez Llorente, Renee Moore, Patricia Rao, Giovanna Scapin, Kenneth J. Simon, Haihong Zhou
  • Anti-lap antibody variants
    Patent number: 11130802
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: September 28, 2021
    Assignees: Tilos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Randall Burton, Jessie M. English, Barbara S. Fox, Stavros Kopsiaftis, Renee Moore, Patricia Rao, Kenneth J. Simon
  • ANTI-LAP ANTIBODY VARIANTS AND USES THEREOF
    Publication number: 20200140530
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Application
    Filed: October 9, 2019
    Publication date: May 7, 2020
    Inventors: Randall BURTON, Jessie M. ENGLISH, Barbara S. FOX, Stavros KOPSIAFTIS, Yacob GOMEZ LLORENTE, Renee MOORE, Patricia RAO, Giovanna SCAPIN, Kenneth J. SIMON, Haihong ZHOU